Strong Data Have Nitec Eying 2010 Filing in RA for Lodotra Sep. 2, 2009 By Cormac Sheridan Nitec Pharma AG has obtained positive data from a second Phase III trial of Lodotra in rheumatoid arthritis (RA), paving the way for a U.S. regulatory filing next year. (BioWorld International)Read More
